TLPH → $3.00 by Dec 26, 2026.

Newer to Investing (11 months in) and insider buying back in February and March for TLPH caught my eye at first. Seth Klarman, Hilary Kramer, and Joel Greenblatt describe pre-revenue biotechs like buying an option. So Talphera (previously AcelRx) is currently testing Nafamostat, a regional anticoagulant medication used during CRRT, whereas no medication has this ability (citrate is not FDA approved for CRRT). They need 70 patients total, and the last quarter they announced about 61% patients signed up. They …